148 related articles for article (PubMed ID: 33997910)
21. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
22. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication).
Baba A; Ojiri H; Goto TK; Ikeda K; Yamauchi H; Ogino N; Mogami T
Jpn Dent Sci Rev; 2019 Nov; 55(1):58-64. PubMed ID: 30815046
[TBL] [Abstract][Full Text] [Related]
23. Relationships of opacification in the nasal sinuses, rhinosinusitis, and antiresorptive agent-related osteonecrosis of the jaw.
Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Saito K
Auris Nasus Larynx; 2020 Dec; 47(6):996-1002. PubMed ID: 32591168
[TBL] [Abstract][Full Text] [Related]
24. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of quantitative bone SPECT/CT for evaluating medication-related osteonecrosis of the jaw treatment response.
Moridera K; Kitajima K; Yoshikawa K; Takaoka K; Tsuchitani T; Noguchi K; Kishimoto H; Yamakado K
Jpn J Radiol; 2023 Jul; 41(7):760-767. PubMed ID: 36656541
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings.
Moridera K; Kitajima K; Yoshikawa K; Takaoka K; Tsuchitani T; Noguchi K; Kishimoto H; Yamakado K
Jpn J Radiol; 2022 May; 40(5):492-499. PubMed ID: 34851501
[TBL] [Abstract][Full Text] [Related]
27. Assessment of inflammatory jaw pathologies using bone SPECT/CT maximum standardized uptake value.
Toshima H; Ogura I
Dentomaxillofac Radiol; 2020 Dec; 49(8):20200043. PubMed ID: 32491931
[TBL] [Abstract][Full Text] [Related]
28. Odontogenic infection and antiresorptive agent-related osteonecrosis of the jaw with facial subcutaneous abscess formation: A retrospective clinical study of difficult-to-diagnose cases.
Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Ogawa M; Saito K
Auris Nasus Larynx; 2021 Aug; 48(4):758-763. PubMed ID: 33436301
[TBL] [Abstract][Full Text] [Related]
29. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience.
Bernardi S; Di Girolamo M; Necozione S; Continenza MA; Cutilli T
Musculoskelet Surg; 2019 Apr; 103(1):47-53. PubMed ID: 29948937
[TBL] [Abstract][Full Text] [Related]
30. Quantification evaluation of
Huang K; Feng Y; Liu D; Liang W; Li L
Ann Nucl Med; 2020 Feb; 34(2):136-143. PubMed ID: 31768820
[TBL] [Abstract][Full Text] [Related]
31. Nonexposed antiresorptive agent-related osteomyelitis of the jaw: a single-center cohort study.
Watanabe T; Yoshida T; Akizuki S; Yamanaka S; Nakao K; Fukuhara S; Asai K; Uozumi R; Bessho K
J Bone Miner Metab; 2022 Jul; 40(4):657-662. PubMed ID: 35534635
[TBL] [Abstract][Full Text] [Related]
32. Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease.
Bedogni A; Fedele S; Bedogni G; Scoletta M; Favia G; Colella G; Agrillo A; Bettini G; Di Fede O; Oteri G; Fusco V; Gabriele M; Ottolenghi L; Valsecchi S; Porter S; Petruzzi M; Arduino P; D'Amato S; Ungari C; Fung Polly PL; Saia G; Campisi G
Br J Oral Maxillofac Surg; 2014 Sep; 52(7):603-8. PubMed ID: 24856927
[TBL] [Abstract][Full Text] [Related]
33. Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.
Kanno C; Kaneko T; Endo M; Kitabatake T; Sakuma T; Kanaya Y; Watanabe Y; Hasegawa H
J Bone Miner Metab; 2021 May; 39(3):423-429. PubMed ID: 33196901
[TBL] [Abstract][Full Text] [Related]
34. Utility of Quantitative Parameters from Single-Photon Emission Computed Tomography/Computed Tomography in Patients with Destructive Thyroiditis.
Kim JY; Kim JH; Moon JH; Kim KM; Oh TJ; Lee DH; So Y; Lee WW
Korean J Radiol; 2018; 19(3):470-480. PubMed ID: 29713225
[TBL] [Abstract][Full Text] [Related]
35. Tc-99m hydroxymethylene diphosphonate SPECT/CT for the evaluation of osteonecrosis of the jaw: preliminary study on diagnostic ability of maximum standardised uptake value.
Ogura I; Sasaki Y; Sue M; Oda T; Kameta A; Hayama K
Clin Radiol; 2020 Jan; 75(1):46-50. PubMed ID: 31699430
[TBL] [Abstract][Full Text] [Related]
36. Quantitative bone scan imaging using BSI and BUV: an approach to evaluate ARONJ early.
Yamamoto Y; Mitsunaga S; Horikawa A; Hino A; Kurihara H
Ann Nucl Med; 2020 Jan; 34(1):74-79. PubMed ID: 31705367
[TBL] [Abstract][Full Text] [Related]
37. Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw.
Dore F; Filippi L; Biasotto M; Chiandussi S; Cavalli F; Di Lenarda R
J Nucl Med; 2009 Jan; 50(1):30-5. PubMed ID: 19091894
[TBL] [Abstract][Full Text] [Related]
38. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.
Schoenhof R; Munz A; Yuan A; ElAyouti A; Boesmueller H; Blumenstock G; Reinert S; Hoefert S
J Craniomaxillofac Surg; 2021 Jun; 49(6):508-517. PubMed ID: 33707134
[TBL] [Abstract][Full Text] [Related]
39. Test-retest repeatability of quantitative bone SPECT/CT.
Yamane T; Fukushima K; Shirotake S; Nishimoto K; Okabe T; Oyama M; Seto A; Kuji I
Ann Nucl Med; 2021 Mar; 35(3):338-346. PubMed ID: 33400148
[TBL] [Abstract][Full Text] [Related]
40. Periosteal reaction of medication-related osteonecrosis of the jaw (MRONJ): clinical significance and changes during conservative therapy.
Soutome S; Otsuru M; Hayashida S; Yanamoto S; Sasaki M; Takagi Y; Sumi M; Kojima Y; Sawada S; Iwai H; Umeda M; Saito T
Support Care Cancer; 2021 Nov; 29(11):6361-6368. PubMed ID: 33884506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
